Machado Patrick
SEC insider (Form 3/4/5 filer). CIK 0001311210. Director at ALUMIS INC. (ALMS) and 4 other issuers. 26 reported Form 4/5 transactions since Sep 2024; latest on Jun 30, 2026. Located in SOUTH SAN FRANCISCO, CA.
Companies Machado Patrick has filed insider reports for
- ALUMIS INC. (ALMS): Director
- Arcus Biosciences, Inc. (RCUS): Director
- Xenon Pharmaceuticals Inc. (XENE): Director
- Adverum Biotechnologies, Inc. (ADVM): Director
- ACELYRIN, Inc. (SLRN): Director
Machado Patrick
CIK: 0001311210
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (26 total)
- Jun 30, 2026ALMS
ALUMIS INC.
AwardDirect3.6K shares- - Jun 11, 2026RCUS
Arcus Biosciences, Inc.
AwardDirect5.7K shares- - Jun 3, 2026XENE
Xenon Pharmaceuticals Inc.
AwardDirectRestricted Share Units
1.6K shares- - Jun 3, 2026XENE
Xenon Pharmaceuticals Inc.
AwardDirectShare Option (Right to Buy)
10.5K shares- - Jun 1, 2026XENE
Xenon Pharmaceuticals Inc.
ExerciseDirect2.6K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Tender OfferDirect8.8K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
DispositionDirectStock Option (Right to Buy)
6.5K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
DispositionDirectStock Option (Right to Buy)
1K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
DispositionDirectStock Option (Right to Buy)
3.4K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
DispositionDirectStock Option (Right to Buy)
3.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 30, 2026 |  ALMS ALUMIS INC. | Award | 3,553 | - | $0 | Direct |
| Jun 11, 2026 |  RCUS Arcus Biosciences, Inc. | Award | 5,700 | - | $0 | Direct |
| Jun 3, 2026 |  XENE Xenon Pharmaceuticals Inc. | Award Restricted Share Units | 1,593 | - | - | Direct |
| Jun 3, 2026 | XENE Xenon Pharmaceuticals Inc. | Award Share Option (Right to Buy) | 10,507 | - | - | Direct |
| Jun 1, 2026 | XENE Xenon Pharmaceuticals Inc. | Exercise | 2,645 | - | $0 | Direct |
| Dec 9, 2025 |  ADVM Adverum Biotechnologies, Inc. | Tender Offer | 8,818 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Disposition Stock Option (Right to Buy) | 6,476 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Disposition Stock Option (Right to Buy) | 1,000 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Disposition Stock Option (Right to Buy) | 3,360 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Disposition Stock Option (Right to Buy) | 3,500 | - | - | Direct |
1-10 of 26 transactions